TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9923794

Group type: COMPARATOR
Intervention: TPN
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TPN plus daily injections of GH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GH and insulin combined with TPN
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GH alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 30
Study: 7586108

Group type: EXPERIMENTAL
Intervention: Pancuronium (120 micrograms.kg‐1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pipecuronium (150 micrograms.kg‐1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pipecuronium
Number of subjects: 27
Study: 1540100

Group type: EXPERIMENTAL
Intervention: Double gloving
Number of subjects: 284

Group type: COMPARATOR
Intervention: Single glove
Number of subjects: 284
Study: 3929312

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.5 - 8.0 mg/day)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo buprenorphine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo buprenorphine plus heroin self-administration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both groups (buprenorphine and placebo plus heroin)
Number of subjects: 7
Study: 29607525

Group type: EXPERIMENTAL
Intervention: LOC remission at end-of-treatment
Number of subjects: 103
Study: 26733703

Group type: EXPERIMENTAL
Intervention: Delayed premium adjustment ($550 incentive)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Immediate premium adjustment ($550 incentive)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Daily lottery incentive ($550 incentive)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group (no financial incentive)
Number of subjects: 197
Study: 25851298

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 5 μg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 2.5 μg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 1.25 μg
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo Respimat®
Number of subjects: 301
Study: 23796683

Group type: EXPERIMENTAL
Intervention: Occupation-based strategy training (adapted version of CO-OP), provided in two 1-hour sessions per week for 10 weeks
Number of subjects: 13
Study: 21664605

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17509694

Group type: EXPERIMENTAL
Intervention: Contactus program (educational program with six lectures and group discussions)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Contactus program
Number of subjects: 319
Study: 16415901

Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 12827578

Group type: EXPERIMENTAL
Intervention: Treatment with antioxidants (vitamin E, vitamin C, allopurinol, and acetylcysteine)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 22
Study: 10857897

Group type: EXPERIMENTAL
Intervention: High-dose intensification (HDCVP): six courses of FAC followed by two courses of cyclophosphamide (5.25 g/m2), etoposide (1,500 mg/m2), and cisplatin (165 mg/m2)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard dose chemotherapy (FAC): 5-fluorouracil, doxorubicin, and cyclophosphamide every 3 weeks for nine courses (control)
Number of subjects: 46
Study: 9766154

Group type: EXPERIMENTAL
Intervention: Diabetic subjects with macrovascular complications
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Diabetic subjects without macrovascular complications
Number of subjects: 69

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69
Study: 7940345

Group type: EXPERIMENTAL
Intervention: Diclonate P (sodium diclofenac)
Number of subjects: 74
Study: 3207540

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Untreated Hypertensive Patients
Number of subjects: 90
Study: 29355435

Group type: EXPERIMENTAL
Intervention: SAR342434 (SAR-Lis)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Ly-Lis (Humalog)
Number of subjects: 1012
Study: 27355239

Group type: EXPERIMENTAL
Intervention: IONIS‐TTRRx (ISIS 420915), a 2nd‐Generation 2'‐O‐(2‐methoxyethyl) modified antisense oligonucleotide (ASO) targeting TTR RNA transcript, administered for four weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IONIS‐TTRRx (ISIS 420915)
Number of subjects: 0
Study: 24796766

Group type: EXPERIMENTAL
Intervention: DHEA (25 mg three times a day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23174579

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control
Number of subjects: 189
Study: 20236550

Group type: EXPERIMENTAL
Intervention: High tidal volume (VT of 10 to 12 ml/kg predicted body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low tidal volume (VT of 5 to 7 ml/kg predicted body weight)
Number of subjects: 20
Study: 18608197

Group type: EXPERIMENTAL
Intervention: 100 mg losartan (ARB)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 5 mg amlodipine (CCB)
Number of subjects: 21
Study: 15719902

Group type: EXPERIMENTAL
Intervention: Preoperative skin antiseptics
Number of subjects: 0
Study: 11790231

Group type: EXPERIMENTAL
Intervention: Transorbital approach using transcranial Doppler
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (all approaches)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (transorbital approach)
Number of subjects: 57
Study: 7486244

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (age/gender-matched controls of normal stature)
Number of subjects: 28
Study: 2686427

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 300 mg IV
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cefotaxime 1000 mg IV
Number of subjects: 106
Study: 7223

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: diazepam and lorazepam
Number of subjects: 28
Study: 31000133

Group type: EXPERIMENTAL
Intervention: Paracetamol (500 mg) every 4 hours when body temperature exceeded 38°C during hospitalisation
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (500 mg) every 4 hours when body temperature exceeded 38°C during hospitalisation
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Paracetamol (500 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (500 mg)
Number of subjects: 125
Study: 28503826

Group type: EXPERIMENTAL
Intervention: Extended chemoradiotherapy (XCRT) - three cycles of fluorouracil based chemotherapy during a 10 week wait period
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (SCRT) - standard 10 week wait period before surgery
Number of subjects: 49
Study: 25910950

Group type: EXPERIMENTAL
Intervention: RT and temozolomide with vandetanib (100 mg daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: RT and temozolomide without vandetanib
Number of subjects: 106
Study: 23422380

Group type: EXPERIMENTAL
Intervention: Duloxetine (DLX) 60 mg once daily for 11 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Escitalopram (ESC) 20 mg once daily for 11 days
Number of subjects: 26
Study: 21046164

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 37
Study: 19296284

Group type: EXPERIMENTAL
Intervention: Indicated early intervention programme led by school staff
Number of subjects: 260

Group type: COMPARATOR
Intervention: Monitoring condition
Number of subjects: 260
Study: 17545499

Group type: EXPERIMENTAL
Intervention: Positively worded living will
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Negatively worded living will
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Forced-choice format living will
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Sample living will representing the default preference
Number of subjects: 233
Study: 14975456

Group type: EXPERIMENTAL
Intervention: Antiproliferative drug‐eluting stents (DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional stenting (bare metal stents)
Number of subjects: 0
Study: 11452321

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered in the buttock (n = 123)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Hepatitis B vaccine administered in the anterolateral thigh muscle (n = 135)
Number of subjects: 258
Study: 9610531

Group type: EXPERIMENTAL
Intervention: 0.4 mg/h transdermal nitroglycerin (NTG) patches
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 7933697

Group type: EXPERIMENTAL
Intervention: Intravitreal hemocoagulase (1 NIH thrombin unit/100 ml in BSS Plus)
Number of subjects: 60

Group type: COMPARATOR
Intervention: BSS Plus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravitreal hemocoagulase
Number of subjects: 60
Study: 3074462

Group type: EXPERIMENTAL
Intervention: Norfloxacin 200 mg b.i.d. for lower UTI; 400 mg b.i.d. for upper UTI
Number of subjects: 172

Group type: COMPARATOR
Intervention: Co-trimoxazole (160 mg of trimethoprim plus 800 mg of sulphamethoxazole) b.i.d. for seven days
Number of subjects: 172
Study: 412580

Group type: EXPERIMENTAL
Intervention: Adjuvant topical mechlorethamine after electron beam therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Electron beam therapy alone
Number of subjects: 100
Study: 31025260

Group type: EXPERIMENTAL
Intervention: Diet containing 108 CFU g−1 Lactobacillus bulgaricus
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Diet containing encapsulated Lactobacillus bulgaricus
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Diet without Lactobacillus bulgaricus
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (normal diet for 45 days, then exposed to Pb)
Number of subjects: 240
Study: 30903342

Group type: EXPERIMENTAL
Intervention: Group C (15 mg/kg IV TXA given on induction, additional doses at 3 hours and 6 hours post-incision)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Group B (15 mg/kg IV TXA given on induction, additional dose at 3 hours post-incision)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Group A (15 mg/kg IV TXA given on induction)
Number of subjects: 180
Study: 28813433

Group type: EXPERIMENTAL
Intervention: COPD without exacerbations
Number of subjects: 18684

Group type: EXPERIMENTAL
Intervention: COPD with exacerbations
Number of subjects: 18684

Group type: EXPERIMENTAL
Intervention: COPD exacerbations post-diabetes
Number of subjects: 18684

Group type: COMPARATOR
Intervention: No COPD
Number of subjects: 18684
Study: 25573400

Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 mg/d), vitamin B6 (50 mg/d), and vitamin B12 (1 mg/d)
Number of subjects: 4331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4331
Study: 23926425

Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) support during treadmill walking
Number of subjects: 22

Group type: COMPARATOR
Intervention: Full weight bearing during treadmill walking
Number of subjects: 22
Study: 22777119

Group type: EXPERIMENTAL
Intervention: Continuous Enteral Nutrition (EN)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous Parenteral Nutrition (PN)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (Orally fed subjects)
Number of subjects: 10
Study: 20537204

Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted sinus excision
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cold steel sinus excision
Number of subjects: 60
Study: 17520052

Group type: EXPERIMENTAL
Intervention: Reduction in ambient sulfate particulate matter due to the copper smelter strike (60% decrease in concentrations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control for time trends, mortality counts in bordering states, and nationwide mortality counts for influenza/pneumonia, cardiovascular, and other respiratory deaths
Number of subjects: 0
Study: 16080074

Group type: EXPERIMENTAL
Intervention: Emtricitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 12513914

Group type: EXPERIMENTAL
Intervention: IL-4 (0.5 microg/kg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IL-4 (1.5 microg/kg/day)
Number of subjects: 17
Study: 10344904

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7908013

Group type: EXPERIMENTAL
Intervention: Taxol at doses ranging between 135 and 175 mg/m2, administered via 3-hour infusion
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Taxol at doses ranging between 135 and 175 mg/m2, administered via 24-hour infusion
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Taxol at higher dose levels and with prolonged infusion
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Taxol
Number of subjects: 107
Study: 2817461

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TDS)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 991548

Group type: EXPERIMENTAL
Intervention: Needle acupuncture at three sites
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhalation of isoprenaline after acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acupuncture at control sites
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acupuncture before and after histamine aerosol challenge
Number of subjects: 20
Study: 30953540

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 4481

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 4481

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg and 10 mg BID)
Number of subjects: 4481
Study: 28114147

Group type: EXPERIMENTAL
Intervention: Feedback group receiving activity and sleep data at each dialysis treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 29
Study: 26431646

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine granules combined with conventional treatment (oxygen uptake, nebulization, anti-infection)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (oxygen uptake, nebulization, anti-infection)
Number of subjects: 60
Study: 23603206

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patch
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content (RNC) cigarettes with 21 mg nicotine patch
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (RNC cigarettes alone)
Number of subjects: 235
Study: 21438804

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg twice daily
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (both doses)
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study: 19803568

Group type: EXPERIMENTAL
Intervention: TAU + YST-II
Number of subjects: 448

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 448
Study: 16969643

Group type: EXPERIMENTAL
Intervention: Minimally invasive unicondylar knee replacement with computer navigation
Number of subjects: 50
Study: 14727390

Group type: EXPERIMENTAL
Intervention: Sport
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Sport Plus
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Sport Plus Parent
Number of subjects: 465

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 465
Study: 11109156

Group type: EXPERIMENTAL
Intervention: Antibacterial soap with 1.5% triclocarban
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo soap
Number of subjects: 50
Study: 9513822

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg bid + Amoxycillin 0.5 g qid
Number of subjects: 267

Group type: COMPARATOR
Intervention: Omeprazole 20 mg bid + Amoxycillin 0.5 g qid
Number of subjects: 267
Study: 8445692

Group type: EXPERIMENTAL
Intervention: Direct Recording Scales
Number of subjects: 38

Group type: COMPARATOR
Intervention: Dial scales (Control)
Number of subjects: 38
Study: 3786575

Group type: EXPERIMENTAL
Intervention: Clomipramin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Desipramin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Imipramin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Carbamazepin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30157179

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) for 20 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 27374467

Group type: EXPERIMENTAL
Intervention: High-dose melphalan (200 mg/m2) and salvage ASCT
Number of subjects: 297

Group type: COMPARATOR
Intervention: Weekly oral cyclophosphamide (400 mg/m2 per week for 12 weeks)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: High-dose melphalan and salvage ASCT
Number of subjects: 297

Group type: COMPARATOR
Intervention: Weekly oral cyclophosphamide
Number of subjects: 297
Study: 24679060

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy plus Roux-en-Y gastric bypass
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy plus sleeve gastrectomy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Surgical groups (gastric bypass and sleeve gastrectomy)
Number of subjects: 150
Study: 22710636

Group type: EXPERIMENTAL
Intervention: Volume-time curve technique
Number of subjects: 267

Group type: COMPARATOR
Intervention: Minimal occlusive volume technique
Number of subjects: 267
Study: 20409546

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study: 17611340

Group type: EXPERIMENTAL
Intervention: Quadruple fluid aerosol inhalation before radiotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (conventional oral care)
Number of subjects: 120
Study: 15660805

Group type: EXPERIMENTAL
Intervention: ICD programmed to DDDR with AVSH
Number of subjects: 1200

Group type: COMPARATOR
Intervention: ICD programmed to VVI-40
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Observational arm with RV pacing > or =20%
Number of subjects: 1200
Study: 11932301

Group type: EXPERIMENTAL
Intervention: 100 microg T(3) after placebo pretreatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo after placebo pretreatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 100 microg T(3) after dobutamine pretreatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 100 microg T(3) after esmolol pretreatment
Number of subjects: 18
Study: 10223774

Group type: EXPERIMENTAL
Intervention: R(+)‐ketorolac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S(‐)‐ketorolac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Racemic ketorolac
Number of subjects: 0
Study: 7599918

Group type: EXPERIMENTAL
Intervention: Caffeine 2.1 mg*kg‐1 body weight
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Caffeine 4.3 mg*kg‐1 body weight
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Caffeine 8.6 mg*kg‐1 body weight
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Caffeine (all doses)
Number of subjects: 37
Study: 1692228

Group type: EXPERIMENTAL
Intervention: Sucralfate mouth swishing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 464783

Group type: EXPERIMENTAL
Intervention: Pressure gradient glove
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control glove
Number of subjects: 15

Group type: COMPARATOR
Intervention: No glove
Number of subjects: 15
Study: 31504798

Group type: EXPERIMENTAL
Intervention: Active screening group (annual invitation for low-dose computed tomography for 4 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis for active screening group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intention-to-treat analysis for usual care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participation in the smoking cessation program (specific to the scan group from one center)
Number of subjects: 0
Study: 30656753

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 154

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 154
Study: 28213300

Group type: EXPERIMENTAL
Intervention: High caregiver stigma reported by caregivers (21%)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Discomfort in disclosing family member's condition (45%)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Association of caregiver stigma with positive symptoms of schizophrenia
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Association of caregiver stigma with higher levels of disability
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Association of caregiver stigma with younger PLS age
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Association of caregiver stigma with household education at secondary school level
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Qualitative themes related to caregiver stigma
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Educational interventions suggested
Number of subjects: 282
Study: 25471444

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training
Number of subjects: 74

Group type: COMPARATOR
Intervention: Neutral control
Number of subjects: 74
Study: 22703939

Group type: EXPERIMENTAL
Intervention: Light-to-moderate-intensity aerobic exercise training (CHF-AET) for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CHF-C)
Number of subjects: 30